Development and validation of an LC-ESI-MS/MS method for simultaneous quantitation of olmesartan and pioglitazone in rat plasma and its pharmacokinetic application

Biomedical Chromatography

Volumn 24, Issue 12, 2010, Pages 1342-1349

  Sengupta, Pinaki ^a   Sarkar, Amlan Kanti ^a   Bhaumik, Uttam ^a   Chatterjee, Bappaditya ^a   Roy, Bikash ^a   Chakraborty, Uday Shankar ^a   Pal, Tapan Kumar ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

LC MS MS; Olmesartan and pioglitazone; Pharmacokinetic application; Rat plasma; Validation

Indexed keywords

BODY FLUIDS; ELECTROSPRAY IONIZATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PRESSURE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PLASMA STABILITY; POSITIVE IONS; RATS;

LC-ESI-MS/MS; LC-MS-MS; LC.MS/MS; LC/ESI-MS/MS; OLMESARTAN AND PIOGLITAZONE; PHARMACOKINETIC APPLICATION; PIOGLITAZONE; RAT PLASMA; SIMPLE++; VALIDATION;

PHARMACOKINETICS;

FORMIC ACID; METHANOL; OLMESARTAN; PIOGLITAZONE; ROSIGLITAZONE; WATER;

ACCURACY; ANALYTIC METHOD; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CALIBRATION; CONTROLLED STUDY; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRACTICE GUIDELINE; QUADRUPOLE MASS SPECTROMETRY; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RAT; REPRODUCIBILITY; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION STUDY;

RATTUS;

EID: 78449259050     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1447     Document Type: Article

References (26)

1. Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubota N, Saito T, Masuda Y, Kadowaki T and Komuro I. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 2002; 105: 1240-1246.
2. Campia U, Matuskey LA and Panza JA. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 2006; 113: 867-875.
3. Dams R, Huestis MA, Lambert WE and Murphy CM. Matrix effect in bioanalysis of illicit drugs with LC-MS/MS: influence of ionization type, sample preparation, and biofluid. Journal of American Society for Mass Spectrometry 2003; 14: 1290-1294.
4. Dongyang L, Pei H, Nobuka M, Xiaoming L, Li L and Ji J. Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. Journal of Chromatography B 2007; 856: 190-197.
5. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U and Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the Proactive Study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. The Lancet 2005; 366: 1279-1289.
6. Food and Drug Administration of the United States. Guidance for Industry-Bioanalytical Method Validation. US Department of Health and Human Services, Center for Drug Evaluation and Research, Center for Veterinary Medicine, 2001. Available from.
7. Gaillard V, Casellas D, Seguin-Devaux C, Schohn H, Dauca M, Atkinson J and Lartaud I. Pioglitazone improves aortic wall elasticity in a rat model of elastocalcinotic arteriosclerosis. Hypertension 2005; 46: 372-379.
8. Ishibashi M, Egashira K, Hiasa K, Inoue S, Ni W, Zhao Q, Usui M, Kitamoto S, Ichiki T and Takeshita A. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002; 40: 687-693.
9. Joner M, Farb A, Cheng Q, Finn AV, Acampado E, Burke AP, Skorija K, Creighton W, Kolodgie FD, Gold HK and Virmani R. Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1. Arteriosclerosis Thrombosis and Vascular Biology 2007; 27: 182-189.
10. Julius S. Hemodynamic and neurohumoral evidence of multifaceted pathophysiology in human hypertension. Journal of Cardiovascular Pharmacology 1990; 15: S53-S58.
11. Kim S and Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacological Reviews 2000; 52: 11-34.
12. Koike H. New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist. American Journal of Cardiology 2001; 87: 33C-36C.
13. Koike H, Sada T and Mizuno M. Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Journal of Hypertension 2001; 19: S3-S14.
14. Lakshmi KS, Rajesh T and Sharma S. Simultaneous determination of metformin and pioglitazone by reversed phase HPLC in pharmaceutical dosage forms. International Journal of Pharmacy and Pharmaceutical Sciences, 2009; 1: 162-166.
15. Langenfeld MR, Forst T, Hohberg C, Kann P, Lubben G, Konrad T, Fullert SD, Sachara C and Pfutzner A. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005; 111: 2525-2531.
16. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB, Perez A, Provost JC and Haffner SM. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. The Journal of American Medical Association 2006; 296: 2572-2581.
17. Mizuno M, Sada T, Kato M and Koike H. Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes. Hypertension Research 2002; 25: 271-278.
18. Mochizuki S, Dahlof B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, Ohta M, Yamada T, Ogawa K, Kanae K, Kawai M, Seki S, Okazaki F, Taniguchi M, Yoshida S and Tajima N. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. The Lancet 2007; 369: 1431-1439.
19. Nakamura T, Yamamoto E, Kataoka K, Yamashita T, Tokutomi Y, Dong Y, Matsuba S, Ogawa H and Kim-Mitsuyama S. Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Hypertension 2008; 51: 296-301.
20. Navar LG, Kobori H and Prieto-Carrasquero MC. Intrarenal angiotensin II and hypertension. Current Hypertension Reports 2003; 5: 135-143.
21. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S and Pocock S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. The Lancet 2003; 362: 759-766.
22. Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P and Diener HC. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36:1218-1226.
23. Sherri LK, Victoria SD and David WB. Controlling hypertension in patients with diabetes. American Family Physician 2002; 66: 1209-1214.
24. Xue YJ, Turner KC, Meeker JB, Pursley J, Arnold M and Unger S. Quantitative determination of pioglitazone in human serum by direct-injection high-performance liquid chromatography mass spectrometry and its application to a bioequivalence study. Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences 2003; 795: 215-226.
25. Yanagisawa H, Amemiya Y, Kanazaki T, Shimoji Y, Fujimoto K, Kitahara Y, Sada T, Mizuno M, Ikeda M, Miyamoto S, Furukawa Y and Koike H. Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds. Journal of Medicinal Chemistry 1996; 39: 323-338.
26. Yki-Jarvinen H. Thiazolidinediones. New England Journal of Medicine 2004; 351: 1106-1118.